Kerry Conlin
she/her/hers
About
Research
Publications
2026
Temporal trends and sociodemographic differences in influenza vaccination among U.S. cancer survivors, 2005-2024.
Conlin K, Mszar R, Ma Z, Cartmel B, Dinan M, Irwin M, Ferrucci L. Temporal trends and sociodemographic differences in influenza vaccination among U.S. cancer survivors, 2005-2024. Journal Of Clinical Oncology 2026, 44: 1674-1674. DOI: 10.1200/jco.2026.44.16_suppl.1674.Peer-Reviewed Original ResearchU.S. cancer survivorsannual percent changehistory of cancercancer survivorsself-reported historyvaccination prevalenceyoung survivorssample of cancer survivorsnon-Hispanic white survivorsNational Health Interview Surveysurvey-weighted logistic regression modelsfactors associated with influenza vaccinationHealth Interview Surveyannual prevalence estimatestemporal trendsinfluenza vaccineprevalence of influenza vaccinationpublic health strategiesuptake of seasonal influenza vaccinationlogistic regression modelsHispanic survivorsWhite survivorshealth strategiesInterview Surveysociodemographic differencesDifferences in the receipt of recommended cardiovascular assessment among cancer survivors in the United States by atherosclerotic cardiovascular disease status.
Mszar R, Alpert A, Gallardo-Vara E, Kang E, Conlin K, Barac A, Hull S, Baldassarre L, Dinan M, Irwin M, Ferrucci L. Differences in the receipt of recommended cardiovascular assessment among cancer survivors in the United States by atherosclerotic cardiovascular disease status. Journal Of Clinical Oncology 2026, 44: 12027-12027. DOI: 10.1200/jco.2026.44.16_suppl.12027.Peer-Reviewed Original Researchcancer survivorsatherosclerotic cardiovascular diseaseproportion of cancer survivorsNational Health Interview Surveypre-existing atherosclerotic cardiovascular diseaseHealth Interview Surveyconfidence intervalsinitial cancer diagnosisnoninstitutionalized U.S. populationpast-yearcardiovascular disease statusmultivariate logistic regressioncancer survivorshipscreening ratescross-sectional datalevel of educationInterview Surveysociodemographic characteristicssocioeconomic statussuboptimal uptakemultistage samplingodds ratiocancer diagnosisSelf-ReportU.S. population
2025
Personalized risk assessment of frailty in long-term cancer survivors
Forman R, Westvold S, Long J, Fan J, Hyslop T, Conlin K, Jacobson S, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of frailty in long-term cancer survivors. Journal Of Geriatric Oncology 2025, 17: 102804. PMID: 41319472, DOI: 10.1016/j.jgo.2025.102804.Peer-Reviewed Original ResearchConceptsfrailty indexpersonalized risk assessmentdelivery of survivorship carestage I-III breastcancer diagnosislong-term cancer survivorscancer survivor populationassessment of frailtyclinical prediction rulesurvivorship carefive-year survivorscancer survivorssurvivor populationfrailty progressionpost-diagnosisMedicare datarisk stratification toolhigh-risk groupRestricted mean survival timefrailtyEnd Resultssignificant predictorslong-term survivorssurvivorsstratification toolCardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer
Westvold S, Long J, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. Journal Of The National Cancer Institute 2025, 118: 130-140. PMID: 41069232, DOI: 10.1093/jnci/djaf243.Peer-Reviewed Original ResearchThis study investigates cardiovascular risk in older long-term cancer survivors, showing non-cancer factors, rather than cancer-specific ones, predict late-onset cardiovascular disease.Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
Feng S, Bibi S, Aley P, Cappuccini F, Clutterbuck E, Conlin K, Ebrahimi N, Eordogh A, Faust S, Felle S, Green J, Gill H, Mujadidi Y, Oladunjoye I, Owino N, Plested E, Robinson H, Stuart A, Voysey M, Pollard A, Lambe T. Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study. Journal Of Infection 2025, 90: 106423. PMID: 39826861, DOI: 10.1016/j.jinf.2025.106423.Peer-Reviewed Original Research
2024
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Conlin K, Jenkin D, de Whalley P, Weckx L, Folegatti P, Bibi S, Lambe T, Aley P, Pollard A, Voysey M, Clemens S, Group C. Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial. Vaccine 2024, 45: 126582. PMID: 39675209, DOI: 10.1016/j.vaccine.2024.126582.Peer-Reviewed Original ResearchPaediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology
Martin N, Defres S, Willis L, Beckley R, Hardwick H, Coxon A, Kadambari S, Yu L, Liu X, Galal U, Conlin K, Griffiths M, Kneen R, Nadel S, Heath P, Kelly D, Solomon T, Sadarangani M, Pollard A, groups O. Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology. Journal Of Infection 2024, 88: 106145. PMID: 38552719, DOI: 10.1016/j.jinf.2024.106145.Peer-Reviewed Original ResearchConceptsclinical decision rulebacterial meningitiscerebrospinal fluidcerebrospinal fluid white blood cell countBacterial Meningitis Scorewhite blood cell countnegative predictive valuechildren aged <aged 6 monthsblood cell countviral meningitisbacterial aetiologyclinical characteristicslumbar puncturevaccine erameningitisclinical syndromecell countpredictive valueclinical decision modelNeisseria meningitidis
2023
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers
McCann N, Emary K, Singh N, Mclean F, Camara S, Jones E, Kim Y, Liu X, Greenland M, Conlin K, Hill J, Verheul M, Robinson H, Angus B, Ramasamy M, Levine M, Pollard A. Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers. BMJ Open 2023, 13: e068966. PMID: 37225278, PMCID: PMC10230971, DOI: 10.1136/bmjopen-2022-068966.Peer-Reviewed Original ResearchConceptshuman challenge modelParatyphi AParatyphi A infectionefficacy trialstreated with antibioticsSalmonella paratyphi Ahealthy adult volunteersclinical diagnostic criteriaMedical Research Ethics Committeeplacebo grouplive attenuated vaccinesenteric feverphase I/IIrandomised controlled trialsclinical developmentvaccine efficacyadult volunteersControlled Trials